Citations

Clear

879 citation(s) found for "Fernandez, G".

Histone lysine methyltransferases KMT2C and KMT2D join the all-star tumor suppressor team in gastrointestinal cancer
Ruiz, Nicole M. Peña, Fernandez-Zapico, Martin E., Peña Ruiz, Nicole M, Ruiz, Nicole M. Pena , Fernández-Zapico, Martín E.

Mayo Clinic

Journal of Clinical Investigation | July 14, 2026 | Volume: 136 | Issue: 14 | Pages: No page available

10.1172/jci208392 | PMID 42454496 Get It

Members of the type 2 histone lysine methyltransferase family (KMT2s) are key drivers of enhancer activation and are the most mutated group of epigenetic regulators in different cancer types. Within this family, KMT2C and KMT2D have the highest mutational incidence across various cancers. To evaluate their role in gastric cancer, Wang et al. developed a Pten deficiency–driven genetically engineered mouse model with inducible loss of Kmt2c and Kmt2d in gastric epithelial cells. Through extensive in vitro, in vivo, and in silico analyses, the authors revealed that the concomitant loss of Kmt2c and Kmt2d promotes gastric carcinogenesis while enhancing antigen presentation and sensitivity to immunotherapy and targeted approaches like mTOR inhibition, highlighting the tumor-suppressive roles of KMT2C/D in gastric cancer and uncovering a vulnerability for this dismal condition.
Digital biomarkers in cardiovascular medicine: a scientific statement of the ESC Working Group on e-Cardiology, the ESC Working Group on Cardiovascular Pharmacotherapy, the European Heart Rhythm Association (EHRA) of the ESC, the Association for Acute Card
Corredoira, Pablo Manuel Fernández, Kaski, Juan Carlos, Duncker, David , Tubaro, Marco , Schuuring, Mark J. , Mamas, Mamas, Petersen, Steffen E, Kemps, Hareld M C, Locati, Emanuela T, Hill, Loreena, Keser, Nurgül , Verstrael, Axel , Friedman, P A, Casado-Arroyo, Rubén , Corredoira, Pablo M , Dörr, Marcus , Wilhelm, Matthias , Schuuring, Mark J , Mueller, Christian , Dilaveris, Polychronis E , Casado-Arroyo, Rubén , Duncker, David , Kaski, Juan Carlos , Wilhelm, Matthias , Petersen, Steffen E. , Vidal-Pérez, Rafael , Jensen, Magnus Thorsten , LUCIA, RAFFAELE DE , Hill, Loreena , Ramírez, Julia , Cluitmans, Matthijs J M , Friedman, Paul A.

Mayo Clinic

European Heart Journal - Digital Health | July 14, 2026 | Volume: 7 | Issue: 6 | Pages: No page available

10.1093/ehjdh/ztag074 | PMID 42491935 Get It

Abstract Cardiovascular disease is the leading cause of morbidity and mortality globally, imposing a substantial patient burden. Digital biomarkers derived from digital health technologies enable quantifiable, near-continuous, real-world capture of pathophysiological signals and are increasingly used across cardiovascular medicine. Their growth is often supported by big data analytics, artificial intelligence and connected sensors within the Internet of Things. This scientific statement systematically reviews digital biomarkers, their clinical utility across the cardiovascular care continuum, and summarizes major methodological and implementation challenges. We searched PubMed/MEDLINE, Embase and Scopus for phase III–IV cardiovascular trials published between 1 January 2019 and 1 August 2024 that collected digital biomarkers. We identified 541 records and included 32 trials (40 reports) enrolling 32 246 participants (44.71% women; mean age 66.2 ± 11.0 years). Heart failure was the most frequent target condition (16 trials, 50%), followed by cardiac implantable electronic devices trials (12 trials, 38%). Digital biomarkers included cardiac rhythm and heart rate, blood pressure, body weight, impedance-based measures, haemodynamic pressures, and physical activity and sleep patterns captured using diverse sensor technologies. Methodological quality was good (modal quality score 5; range 3–7), although most trials were unblinded. Current studies suggest potential clinical utility in selected cardiovascular conditions. Implementation remains challenging because of measurement variability, privacy and regulatory requirements, affordability and reimbursement barriers and inequities in access. Robust validation and outcome- and cost-effectiveness evidence are still needed. Registration number: CRD42024573879.
Albumin Therapy for Advanced Liver Disease: New Data from the EASL Congress 2026
Kim, W. Ray, Pompil, Enrico, Fernández, Javier, Biswas, Sagnik, Sood, Siddharth , Biswas, Sagnik

Mayo Clinic

EMJ Hepatology | July 13, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.33590/emjhepatol/1h7598io Get It

The role of human albumin therapy in the management of advanced liver disease is not yet fully established across all settings and remains a topic of debate. The significant and complicated burden of the disease, coupled with limited therapeutic options, presents ongoing challenges. At the European Association for the Study of the Liver (EASL) Congress 2026, studies in patient populations worldwide delivered new insights to add to the debate on the use of human albumin therapy at the most severe end of the liver disease spectrum. This article reviews a selection of the latest data, evaluating long-term albumin therapy for decompensated cirrhosis, as well as Phase III study evidence on the use of therapeutic plasma exchange (TPE) for acute-on-chronic liver failure (ACLF).
Albumin Therapy for Advanced Liver Disease: New Data from the EASL Congress 2026
Kim, W. Ray, Pompil, Enrico, Fernández, Javier, Biswas, Sagnik, Sood, Siddharth , Biswas, Sagnik

Mayo Clinic

EMJ Hepatology | July 13, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.33590/emjhepatol/1h7598io. Get It

The role of human albumin therapy in the management of advanced liver disease is not yet fully established across all settings and remains a topic of debate. The significant and complicated burden of the disease, coupled with limited therapeutic options, presents ongoing challenges. At the European Association for the Study of the Liver (EASL) Congress 2026, studies in patient populations worldwide delivered new insights to add to the debate on the use of human albumin therapy at the most severe end of the liver disease spectrum. This article reviews a selection of the latest data, evaluating long-term albumin therapy for decompensated cirrhosis, as well as Phase III study evidence on the use of therapeutic plasma exchange (TPE) for acute-on-chronic liver failure (ACLF).
Real-World Practice in Secondary Stroke Prevention Following Embolic Stroke of Undetermined Source
Nour, Hassan Aboul , Siegler, James E. , Thompson, Sean, Glover, Patrick , Daniel, J, Penckofer, Mary , Smith, M A, Yaghi, Shadi , Chen, L, Kerrigan, Deborah , Kirchhoffer, Kaitlyn, Kam, Wayneho , Melkumova, Emiliya , Lineback, Christina , Thottempudi, Neeharika , Heaton, Sharon, Linares, Guillermo , Singh, Eesha , Fernández, Camilo José Albert, Dumitrașcu, Oana , Bowman, Anna, Porto, Camelia Valhuerdi, Chahien, Dalia, Herpich, Franziska , Kang, Jieun , Nelson, Ashley , Shahrivari, Mahan, Khezri, Nicole, Lewis, Skylar, Sathya, Anvitha , Leung, Lester Y. , Eklund, Kelsey , Rojas-Soto, Diana , Nedelcu, Simona , Kasab, Sami Al , Coevering, Russell J. Van, Thon, Jesse , Aboul-Nour, Hassan , Siegler, James E , Thompson, Sean L , Glover, Patrick , Daniel, Jean-Philippe Auguste , Smith, Matthew M , Ro, Jennifer , Chen, Lucia , D'Souza, Marissa , Khasiyev, Farid , Kerrigan, Deborah , Sharma, Richa , Aziz, Yasmin , Kirchhoffer, Kaitlyn , Kam, Wayneho , Melkumova, Emiliya , Sloane, Kelly L , Lineback, Christina M , Thottempudi, Neeharika , Heaton, Sharon , Linares, Guillermo , Almallouhi, Eyad , Stretz, Christoph , Dumitrascu, Oana M , Culbertson, Collin J , Elangovan, Cheran , Bowman, Anna , Valhuerdi Porto, Camelia , Chahien, Dalia , Herpich, Franziska , Farooqui, Mudassir , Kang, Jieun , de Havenon, Adam H , Nelson, Ashley , Shahrivari, Mahan , Stamm, Brian , Khezri, Nicole , Lewis, Skylar , Sathya, Anvitha , Leung, Lester Y , Eklund, Kelsey , Rojas-Soto, Diana , Nedelcu, Simona , Al Kasab, Sami , Thon, Jesse , Jillella, Dinesh V , Nahab, Fadi B , Yaghi, Shadi , Penckofer, Mary , D’Souza, Marissa , Khasiyev, Farid , Sharma, Richa , Aziz, Yasmin , Almallouhi, Eyad , Stretz, Christoph , Elangovan, Cheran , Havenon, Adam de , Stamm, Brian , Coevering, Russell J. Van , Jillella, Dinesh

Mayo Clinic

Neurology Clinical Practice | July 10, 2026 | Volume: 16 | Issue: 4 | Pages: No page available

10.1212/cpj.0000000000200631 | PMID 42430672 Get It

Comparing Complications Between Shape‐Sensing Robotic‐Assisted Bronchoscopy and Trans‐Thoracic Needle Pulmonary Biopsy Approaches: Insights From a Large Nationally Representative Administrative Database
Abia‐Trujillo, David , Fernandez-Bussy, S, Husta, B C, Milky, Gediwon , Wing, Sam E., Gaertner, Adam, Oh, Scott , Abia-Trujillo, David , Folch, Erik E. , Wing, Sam E.

Mayo Clinic

Thoracic Cancer | July 10, 2026 | Volume: 17 | Issue: 13 | Pages: No page available

10.1111/1759-7714.70324 | PMID 42425909 Get It

ABSTRACT Background Shape‐sensing robotic‐assisted bronchoscopy (ssRAB) is a navigation platform for biopsy of indeterminate pulmonary lesions. Large‐scale, real‐world evidence confirming the safety profile of ssRAB compared to transthoracic needle biopsy (TTNB) is needed. Study Design and Methods A retrospective cohort study was performed using the PINC AI healthcare database among patients who underwent ssRAB or TTNB lung lesion biopsy at participating hospitals between April 2019 and March 2023. Outcomes were rates of pneumothorax and pneumothorax requiring chest‐tube intervention within 3 days, and rates of in‐hospital bleeding or all‐cause death. Quasi‐binomial logistic regression analysis was performed after one‐to‐five propensity score matching (PSM) accounting for patient‐ and hospital‐related characteristics. Results A total of 119 424 patients (5121 ssRAB, 114 303 TTNB) were identified with 4554 ssRAB and 14 319 TTNB patients after PSM. Relative to ssRAB, TTNB had significantly higher risk of pneumothorax (18.4% vs. 2.6%, OR = 7.10, p < 0.001) and pneumothorax requiring chest‐tube (10.8% vs. 1.4%, OR = 7.62, p < 0.001). TTNB was associated with a higher risk for bleeding (1.5% vs. 0.6%, OR = 2.20, p < 0.001) and all‐cause death (0.48% vs. 0.15%, OR = 2.47, p = 0.023); however, rates for both outcomes were relatively low. Interpretation In this large‐scale, real‐world database analysis with diverse patient populations, physician experience, and health care settings, ssRAB demonstrated a better safety profile compared to TTNB. Superior safety combined with a potentially comparable performance profile and known advantages of bronchoscopy, including concurrent staging, support ssRAB as an optimal choice for non‐surgical biopsies for suspicious pulmonary lesions.
Cross-definition GWAS of IBS in 2.8 million individuals reveals cardiometabolic and triglyceride-linked mechanisms
Lorenzo, Biagio Di, Tavares, Letícia Camargo , Díaz-Muñoz, Cristian , Heredia-Fernández, Francisco , Bozzarelli, Isotta, Blanco, Cristina Esteban, Wang, Zhe, Smit, Roelof A J, Loos, Ruth J F, Hirbo, Jibril, Cox, Nancy J, Straub, Peter, Favé, Marie-Julie , Pozdeyev, Nikita, Gignoux, Christopher R, Gudbjartsson, Daniel F, Thorleifsson, Gudmar, Jónsdóttir, Ingileif , Stefansson, Kari, Palta, Priit, Sze, Gerald , John, Catherine, Richmond, Anne, McCartney, Daniel, Hayward, Caroline, Mulford, Ashley J, Sanders, Alan R, Dombrovska, Marija Simona, Capasso, Mario, Faro, Valeria Lo, Maya, Esteban Alexander Lopera, Zhernakova, A, Cohort, Lifelines, Martin, Alicia, Vanderwerff, Brett , Zöllner, Sebastian, Ferolito, Brian R. , Pereira, Alexander Castanho, Gaziano, J. Michael , Caruth, Lanna, Guare, Lindsay, Kripke, Colleen Morse , Rader, Daniel J, Verma, Shefali S, Verma, Anurag, BioBank, Penn Medicine, Saad, Chadi, Chao, Pei-Yu, Chen, Tzu-Ting, Lin, Yen-Feng, Feng, Yen‐Chen Anne , Khalili, Hamed , Andries, Aristomo , Ness‐Jensen, Eivind , Grover, Madhusudan , FinnGen, Lemmelä, Susanna, Abner, Erik , Challa, Prasanna K , Khalili, Hamed , Ness-Jensen, Eivind , Grover, Madhusudan , D'Amato, Mauro , Loos, Ruth J F , Camargo Tavares, Leticia , Lorenzo, Biagio Di , Smit, Roelof A. J. , Loos, Ruth J. F. , Hirbo, Jibril B , Cox, Nancy J., Awadalla, Philip , Pozdeyev, Nikita V. , Gignoux, Chris , Gudbjartsson, Daniel Fannar , Þorleifsson, Guðmar , Priit, Palta , Williams, Alexander T. , Coley, Kayesha , John, Catherine , Richmond, Anne , Mulford, Ashley J. , Pečulis, Raitis , Rovīte, Vita , Capasso, Mario , Faro, Valeria Lo , Sinha, Trishla , Lopera-Maya, Esteban A. , Zhernakova, Alexandra , Wang, Ying, Vanderwerff, Brett , Zöllner, Sebastian , Cho, Kelly , Guare, Lindsay A. , Rader, Daniel J , Verma, Shefali S. , Saad, Chadi , Mbarek, Hamdi , Brumpton, Ben , Lemmelä, Susanna M. , Sanna, Serena , Bonfiglio, Ferdinando , D’Amato, Mauro

Mayo Clinic

Gut | July 9, 2026 | Volume: No volume available | Issue: No issue available | Pages: gutjnl-2026-338800

10.1136/gutjnl-2026-338800 | PMID 42425734 Get It

Background Irritable bowel syndrome (IBS) is a complex disorder of gut-brain interaction, with heterogeneous symptoms, no available biomarkers and limited pathogenetic insight. Objective To identify genetic risk factors and actionable mechanisms for future clinical translation in IBS. Design We conducted a genome-wide association study (GWAS) meta-analysis of IBS in 2 775 539 individuals from 22 biobanks. IBS genetics was studied across multiple ancestries, different case definitions and symptom-related subtypes. Heritability and genetic correlations with other traits were estimated, and Mendelian randomisation was used to test causal relationships. GWAS data were functionally annotated and fine-mapped to prioritise tissues, cell types, pathways, candidate genes, specific mechanisms and druggable targets. Results Significant heritability was only detected in individuals of European ancestry, with near-identical genetic architecture across case definitions. Genetic correlations with GI, psychiatric and cardiometabolic traits were observed, including causal relationships with triglyceride (TG) levels. Functional annotation of IBS risk loci highlighted cell types and pathways relevant to brain, enteric neuro-glial and cardiometabolic domains, as well as actionable targets like GCKR, a regulator of TG metabolism. Druggability analyses converged on cardiometabolic mechanisms, including TG modulation. IBS polygenic risk scores were derived and showed a significant association with case status in an independent case-control dataset, supporting further evaluation in external population-based and clinically ascertained cohorts. Conclusions This study provides the most comprehensive assessment of IBS genetics to date, demonstrating reproducible polygenic inheritance. We link IBS risk to convergent neurogastrointestinal and novel cardiometabolic mechanisms, highlight specific biological pathways and actionable mechanisms and outline translational opportunities emerging from integrated computational analyses.
Early Versus Late Recurrence in Olfactory Neuroblastoma: A Multi‐Institutional Analysis of Predictive Risk Factors
Harris, Alexandria , Tang, Anthony, Fung, Nicholas , Champagne, Pierre‐Olivier, Fernandez-Miranda, Juan, Gardner, Paul A. , Hwang, Peter H. , Kalyvas, Aristotelis, Patel, Zara M. , Patel, Zara M., Celda, María Peris, Pinheiro-Neto, Carlos D., Sanusi, Olabisi, Thorp, Brian D., Gompel, Jamie J. Van, Zenonos, Georgios, Zwagerman, Nathan T., Bell, Diana, Kuan, Edward C., Geltzeiler, Mathew, Hwang, Peter H , Patel, Zara , Snyderman, Carl H , Wang, Eric W , Choby, Garret , Tang, Anthony , Almeida, João Paulo , Champagne, Pierre‐Olivier , Kalyvas, Aristotelis , Pinheiro‐Neto, Carlos , Sanusi, Olabisi , Thorp, Brian D. , Gompel, Jamie J. Van , Zenonos, Georgios A. , Zwagerman, Nathan T. , Bell, Diana , Kuan, Edward C , Geltzeiler, Mathew , Choby, Garret

Mayo Clinic

International Forum of Allergy & Rhinology | July 9, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/alr.70216 | PMID 42422976 Get It

ABSTRACT Background Olfactory neuroblastoma (ONB) exhibits variable recurrence patterns, with significant late recurrences occurring years after treatment. We investigated cutoff periods to define late recurrence and identified predictors that distinguish patients at risk of late recurrence from those considered cured. Methods From a multi‐institutional cohort of 219 ONB patients treated at nine centers, we analyzed 77 patients with documented recurrence. Using a 48‐month cutoff to define early (< 48 months) versus late (≥ 48 months) recurrence, we evaluated 35 clinical, anatomic, and treatment variables using Firth penalized logistic regression across three comparisons: (1) late versus early recurrence timing, (2) late recurrence versus no recurrence, and (3) early recurrence versus no recurrence. Results Thirty‐four of the 77 (44.2%) recurrences were classified as late. Among the 77 patients who recurred, smaller tumor volume (OR 0.243, p = 0.035) and lower novel Dulguerov staging (OR 0.802, p = 0.038) were associated with late, rather than early recurrence. When patients with late recurrence were compared to those who remained disease‐free, radiographic skull base bone involvement was the strongest independent predictor (OR 2.90, 95% CI 1.14–8.64, p = 0.025), and this effect strengthened after adjusting for tumor volume (OR 3.80, p = 0.029). Pathologic dural invasion (OR 3.29, p = 0.013), Kadish stage (OR 2.02, p = 0.026), and T‐stage (OR 1.32, p = 0.040) were also significant. Conclusions A 48‐month cutoff effectively stratifies ONB recurrence risk. Skull base bone involvement independently predicts recurrence when compared to nonrecurrent cases and uniquely persists as a risk factor for late recurrence. These findings establish skull base bone involvement as a novel biomarker for risk‐stratified surveillance protocols.
Multidisciplinary Management of Tracheal Perforation: A Case of Successful Reconstruction and Stenting
Valdes‐Camacho, Sofia , Murillo‐Torres, Regina M. , Rojas-Zapata, Tatiana A. , Lee‐Mateus, Alejandra Yu , Gutierrez‐Gallegos, Paola , Valencia, Bastien A. , Anderson, Elise, Robertson, Kelly S , Fernández-Bussy, Sebastián , Janus, Jeffrey R. , Yu Lee-Mateus, Alejandra , Valencia‐Sanchez, Bastien A. , Abia-Trujillo, David , Abia‐Trujillo, David

Mayo Clinic

Respirology Case Reports | July 8, 2026 | Volume: 14 | Issue: 7 | Pages: No page available

10.1002/rcr2.70661 | PMID 42416892 Get It

ABSTRACT Airway perforation is a potentially lethal complication from tracheal or mediastinal malignancies that require complex management. Advanced thyroid cancer is known to have high morbidity, and patients with tracheal metastatic lesions are vulnerable to injury. Therapeutic management typically comprises a combination of surgical and nonoperative treatment modalities, whose adverse effects can lead to significant airway injury. We present the case of a 67‐year‐old man with papillary thyroid carcinoma who developed a tracheocutaneous fistula following proton beam therapy and chemotherapy for metastatic disease. Airway repair and recanalization were successfully achieved through a combined surgical and bronchoscopic approach.
Clinical and Molecular Effects of TYK2/JAK1 Inhibition in Dermatomyositis
Mangold, Aaron, Vleugels, Ruth Ann , Shahriari, Neda , Castillo, Rochelle , Gehlhausen, Jeffrey, Jiang, Rundong , Haemel, Anna Kaye, Fox, Jennifer Callahan, Bogle, Rachael , Roberts, Bryce T. , Penner, Scott , Li, Xing, Ramirez, Zeni , Tsoi, Alex, Shaw, Katharina, Cascino, Matthew, Johnson, BE, Kahlenberg, J. Michelle, Gudjonsson, Johann E., Paik, Julie J. , Sluzevich, Jason C. , Haemel, Anna K. , Bogle, R, Shaw, Katharina S. , Cascino, Matthew D., Kahlenberg, J. Michelle , Christopher‐Stine, Lisa , Fernandez, Anthony P , Fiorentino, David Franklin , Werth, Victoria P. , Gudjonsson, Johann E

Mayo Clinic

No container title available | June 26, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.06.15.26354270 Get It

Abstract Dermatomyositis is driven by overactivation of type I and II interferons and other proinflammatory cytokines that signal via the JAK-STAT pathway. We conducted a 12-week, open-label study of brepocitinib, an oral TYK2/JAK1 inhibitor, in five adults with severe cutaneous dermatomyositis. Treatment was associated with rapid, clinically meaningful improvement in cutaneous disease activity. Single-cell and spatial transcriptomic profiling of lesional skin showed marked suppression of interferon-responsive pathways and inflammatory cell states by week 4. Together with findings from a Phase 3 randomized trial in DM patients with skin and muscle involvement (VALOR, NCT05437263 ), these data support TYK2/JAK1 inhibition as a promising therapeutic strategy for DM.